Trimethadione

This article is about the drug Tridione. For the content management software Tridion, see SDL plc.

Trimethadione

Clinical data
Trade names	Tridione
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	X
Routes of administration	By mouth
ATC code	N03AC02 (WHO)
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	High
Metabolism	Demethylated to dimethadione
Biological half-life	12–24 hours (trimethadione) 6–13 days (dimethadione)
Excretion	Renal
Identifiers
IUPAC name 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione
CAS Number	127-48-0 Y
PubChem (CID)	5576
IUPHAR/BPS	7316
DrugBank	DB00347 Y
ChemSpider	5374 Y
UNII	R7GV3H6FQ4 Y
KEGG	D00392 Y
ChEMBL	CHEMBL695 Y
ECHA InfoCard	100.004.406
Chemical and physical data
Formula	C6H9NO3
Molar mass	143.141 g/mol
3D model (Jmol)	Interactive image
SMILES O=C1N(C(=O)OC1(C)C)C
InChI InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3 Y Key:IRYJRGCIQBGHIV-UHFFFAOYSA-N Y
(verify)

Trimethadione is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.

Fetal trimethadione syndrome

If administered during pregnancy, fetal trimethadione syndrome may result causing facial dysmorphism (short upturned nose, slanted eyebrows), cardiac defects, intrauterine growth restriction (IUGR), and mental retardation. The fetal loss rate while using trimethadione has been reported to be as high as 87%.

External links

• MedlinePlus DrugInfo medmaster-a601127
• DDB 30479